Integrated Quantitative Investments LLC Makes New $738,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Integrated Quantitative Investments LLC bought a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 39,147 shares of the company’s stock, valued at approximately $738,000. Integrated Quantitative Investments LLC owned 0.08% of Pacira BioSciences at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Caitlin John LLC lifted its holdings in Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after buying an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after acquiring an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after purchasing an additional 513 shares during the period. Virtus Investment Advisers Inc. bought a new position in Pacira BioSciences in the third quarter worth approximately $98,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock worth $184,000 after purchasing an additional 918 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PCRX has been the topic of a number of recent research reports. Barclays increased their price target on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. HC Wainwright upped their price target on shares of Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Royal Bank of Canada reissued a “sector perform” rating and set a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. Needham & Company LLC upped their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Finally, Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their price target for the company from $8.00 to $25.00 in a report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $27.22.

Pacira BioSciences Stock Down 4.9 %

PCRX stock opened at $23.10 on Friday. The stock has a market capitalization of $1.07 billion, a PE ratio of -11.38 and a beta of 0.70. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The firm has a 50 day moving average of $24.88 and a 200 day moving average of $20.29.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.